What SABI Mind does

SABI Mind Inc. is a Calgary, Alberta-based private healthcare company operating psychedelic-assisted therapy clinics for treatment-resistant mental health and chronic pain conditions. Founded in March 2022, the company runs two healing centres — its Calgary flagship in Sunalta and a second location in Victoria, British Columbia opened in April 2024 — delivering a three-phase care model (Preparation, Discovery, Integration) anchored on intramuscular and intravenous ketamine administration and the proprietary ExoMind™ neuromodulation platform built on patented ExoTMS™ repetitive transcranial magnetic stimulation technology, which is Health Canada-cleared for depression.

The company's core products are SABI Therapy for Mental Health and SABI Therapy for Chronic Pain (STCP), both ketamine-led interdisciplinary programs, supplemented by ExoMind™ rTMS therapy, SABI Somatics (body-centered modalities including osteopathic manual therapy, somatic experiencing, and somatic therapy), and dedicated first-responder services under the Beyond The Call sub-brand with a fully covered EXOMIND Support Initiative. SABI Mind also conducts clinical research, including a Health Canada-authorized PsilWell wellness-focused psilocybin therapy trial launched in October 2025 in partnership with TheraPsil, CRIO, and Filament Health, and an earlier Clairvoyant Therapeutics-sponsored alcohol use disorder study. Regulatory credentials include provisional Non-Hospital Surgical Facility (NHSF) accreditation from the College of Physicians and Surgeons of Alberta (November 2024), making SABI Mind the first non-hospital provider of IV ketamine therapy in Alberta.

The revenue model is primarily transactional and per-treatment: program packages priced in the low-thousands CAD range (PsilWell trial at CAD 4,500), with referral discounts, insurance-adjusted pricing, and first-responder subsidies layered on. Customers are predominantly individual patients — mental health sufferers, chronic pain patients, and first responders — acquired through a sales-led, content- and event-driven go-to-market leveraging social media, podcasts, webinars, blog content, and industry conferences. SABI Mind holds trademarked proprietary technology (ExoMind™, ExoTMS™), partnerships with multiple psychedelic compound suppliers (PharmAla, Optimi Health, Filament Health), and operates under Health Canada special access program approvals. As of May 2023, the company had raised only approximately $180,365 USD via an SEC Regulation D offering, indicating a founder-led capital structure rather than institutional-backed scaling.

Name

SABI Mind

Legal name

SABI MIND INC.

Website

https://sabimind.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

SABI Mind operates two Canadian psychedelic-assisted therapy clinics in Calgary and Victoria, delivering ketamine and ExoMind rTMS treatments for treatment-resistant mental health and chronic pain conditions, with specialized first-responder programs and active clinical trial participation.

Ownership category

akta.pro rank

Product category

Mental Health & Chronic Pain Treatment Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112), Offices of Mental Health Practitioners (except Physicians) (621330)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Outpatient Mental Health & Counseling Clinics (HLAFABAC)

akta.pro secondary industry

Multidisciplinary Outpatient Rehab Centers (PT/OT/SLP) (HLADAJAG)

Keywords

• Ketamine therapy
• Psychedelic assisted therapy
• Chronic pain treatment
• Transcranial magnetic stimulation
• Mental health clinic

Headquarters

HQ city

Calgary

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Therapeutic Treatment Services: Revenue generated from administering psychedelic-assisted therapies including ketamine treatments, psilocybin therapy, and MDMA-assisted therapy programs. Treatment programs are priced as comprehensive packages including screening, therapy sessions, and follow-up care.
2. Clinical Research Services: Revenue from conducting clinical trials including the PsilWell trial, providing therapeutic services to research participants under Health Canada approvals.
3. EXOMIND Support Programs: Specialized brain health and mental wellness programs offered through the Beyond The Call initiative for first responders, with discounted pricing for program access.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

SABI Mind operates clinical healing centres in Calgary and Victoria, BC, delivering ketamine-assisted psychotherapy, psilocybin-assisted therapy, MDMA-assisted therapy, and ExoMind™ repetitive transcranial magnetic stimulation (rTMS) to patients with treatment-resistant mental health conditions and chronic pain. Treatments follow a three-phase model of Preparation, Discovery, and Integration, with on-site physicians, anesthesiologists, and psychiatrists administering care under Health Canada approvals.

Product overview

SABI Mind is a psychedelic-assisted therapy clinic offering ketamine and rTMS treatments across two Canadian locations (Calgary and Victoria, BC). The core offerings include SABI Therapy for Mental Health and Chronic Pain (using ketamine), and EXOMIND™ (using patented ExoTMS™ rTMS technology). The company provides a three-phase healing approach: Preparation, Discovery, and Integration. Additional services include SABI Somatics (body-centered therapies), counselling, and manual therapy. Beyond The Call is a specialized sub-brand offering mental health services for first responders with reduced pricing. The company also conducts clinical research including psilocybin trials and maintains NHSF accreditation for IV ketamine administration.

Differentiator

Problem solved

Functional benefit

Brands

• EXOMIND: A groundbreaking mental wellness therapy using patented ExoTMS technology for repetitive transcranial magnetic stimulation (rTMS) to treat symptoms of depression and improve mental health.
• SABI Therapy for Chronic Pain (STCP)
• Beyond The Call
• SABI Somatics
• EXOMIND Support Initiative

Products and services

• SABI Therapy for Mental Health Ketamine-assisted psychotherapy administered intramuscularly by qualified physicians, combined with preparation, discovery, and integration phases for individuals with treatment-resistant depression, PTSD, anxiety, and related mental health conditions.
• SABI Therapy for Chronic Pain (STCP) Interdisciplinary chronic pain program led by chronic pain specialists, using ketamine-assisted therapy combined with integrative therapies for chronic pain conditions.
• EXOMIND™ Non-invasive, drug-free neuromodulation therapy using patented ExoTMS™ repetitive transcranial magnetic stimulation (rTMS) technology, Health Canada-cleared for the treatment of depression.
• Beyond The Call Dedicated mental health platform for first responders (police, firefighters, paramedics) offering EXOMIND therapy, ketamine therapy, and counselling services with reduced pricing and the EXOMIND Support Initiative providing fully covered treatments for eligible first responders.
• SABI Somatics Body-centered mental health service stream offering osteopathic manual therapy, somatic therapy, and somatic experiencing coaching for trauma and nervous system regulation.
• Intravenous (IV) Ketamine Therapy Intravenous ketamine therapy for treatment-resistant mental health conditions and chronic pain, enabled by provisional Non-Hospital Surgical Facility (NHSF) accreditation from the College of Physicians and Surgeons of Alberta.
• PsilWell Wellness-Focused Psilocybin Therapy Trial Wellness-focused psilocybin therapy clinical trial program offering screening, psilocybin-assisted group therapy, and follow-up care for adults aged 18-65, operated in Victoria under Health Canada authorization.
• Equitable Access Program (EAP) Access program providing chronic pain and mental health care to historically underserved, underrepresented, or low-income patient populations at reduced or subsidized pricing.
• Psychedelic-Assisted Therapy (PAT) Therapeutic technique using psychedelic substances administered in low to moderate doses under supervision of trained medical and mental health professionals, available at the Victoria location.
• Therapy & Counselling Evidence-based therapeutic approaches tailored to individual client needs for anxiety, depression, relationship issues, and life transitions, delivered as part of the Preparation and Integration phases.
• Manual Therapy Hands-on manual therapy techniques including osteopathy to manipulate and mobilize muscles and joints, alleviate pain, enhance mobility, and release trauma stored in the body.

Quantifiable outcome

• PsilWell clinical trial: CAD 4,500 per participant program

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and flagship.

• Optimi HealthcoreTechnology or Integration · 1 June 2022Supply partnership for psilocybin and MDMA therapeutic substances used in clinical trials and treatment programs. Optimi Health provides naturally-sourced psychedelic compounds for therapeutic applications.
• Filament Health Corp.coreTechnology or Integration · 1 June 2022Psilocybin supply agreement ensuring availability of pharmaceutical-grade psilocybin for clinical research and patient treatment programs.
• PharmAla BiotechcoreTechnology or Integration · 1 May 2022MDMA supply agreement providing pharmaceutical-grade MDMA for clinical research and therapeutic applications. PharmAla Biotech is a Canadian company specializing in psychoactive compound manufacturing for clinical use.
• Reverie PsychedeliccoreStrategic or Co-development Partner · 1 March 2022Research partnership focused on advancing psychedelic-assisted therapy protocols and clinical research initiatives for mental health treatments.
• TheraPsilcoreStrategic or Co-development PartnerPartnership supporting the PsilWell clinical trial, involving collaboration on psilocybin-assisted therapy research for treatment-resistant conditions.
• Beyond The CallflagshipGTM or Marketing PartnerEXOMIND Support Initiative partnership providing specialized mental health programs for first responders including police, firefighters, and paramedics, with 20% discounted pricing on programs.

Scale indicators2 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Field Trip Health & Wellness: Field Trip Health & Wellness operates psychedelic-assisted therapy clinics across Canada and the US, directly competing with SABI Mind in ketamine and psilocybin-based mental-health treatment in the same patient segment.
• Numinus Wellness: Numinus runs ketamine-assisted therapy clinics in Canada (including British Columbia) and operates a psychedelic research division, overlapping directly with SABI Mind on clinic-based psychedelic therapy in Western Canada.
• ATMA Journey Centers: ATMA operates psychedelic-assisted therapy clinics in Western Canada focused on personal-growth and mental-health programs, competing for the same treatment-resistant patient base as SABI Mind's Calgary and Victoria clinics.

Emerging players

• TheraPsil: TheraPsil is a Canadian non-profit that runs psilocybin-assisted therapy programs and is an active research partner of SABI Mind (PsilWell trial); its clinical and training activities overlap with SABI Mind's psychedelic therapy offerings.
• Clairvoyant Therapeutics: Clairvoyant Therapeutics is a Canadian clinical-stage psychedelic company running psilocybin trials for alcohol use disorder, of which SABI Mind is the first Alberta clinical site — making it an immediate sponsor/customer peer.
• Revive Therapeutics: Revive Therapeutics is a Canadian specialty psychedelics company focused on psilocybin therapeutics, positioning it as an adjacent player in the same psilocybin clinical-research ecosystem in which SABI Mind participates.
• Mycotopia Therapies: Mycotopia Therapies provides psilocybin-based mental-health treatment programs in partnership with Canadian clinics; it competes for the same niche Canadian psilocybin-assisted therapy market as SABI Mind.

Broad incumbents

• MindMed: MindMed is a publicly-traded psychedelic-medicine developer with clinical programs in mental health and a broader, drug-development-focused footprint than SABI Mind's clinical-services business — overlapping at the patient/indication level.
• BrainsWay: BrainsWay manufactures FDA-cleared deep TMS systems used for depression and OCD treatment; SABI Mind's ExoTMS™/ExoMind™ TMS offerings compete for the same clinical indication and provider-customer relationships.
• Cerebral: Cerebral is a large US digital mental-health provider offering telehealth therapy and medication management — a much broader, incumbent mental-health-services operator competing for the same downstream treatment-resistant depression patient demand that SABI Mind addresses.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/sabimind
• Facebookfacebook.com/SABIMIND
• Instagraminstagram.com/sabimind

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SABI Mind